Press Releases

Print Page   Print Page       E-mail Page   Email Page       RSS Feeds   RSS       E-mail Alerts  Email Alerts       Financial Tear Sheet  Tear Sheet

Press Releases

Date Title
04/18/19 Alkermes to Host Conference Call to Discuss First Quarter 2019 Financial Results
04/09/19 Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia
04/08/19 Alkermes Announces Departure of Jim Robinson
04/03/19 Alkermes Expands Awards Program With Focus on Advancing Research in Schizophrenia
04/01/19 Alkermes to Present New ALKS 3831 Data From ENLIGHTEN-2 and Interim Extension Safety Study Results at 2019 Congress of the Schizophrenia International Research Society
03/21/19 Alkermes Statement on National Academies of Sciences, Engineering, and Medicine Report on Medications for Opioid Use Disorder
03/05/19 Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 39th Annual Health Care Conference
02/26/19 Alkermes Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in Patients With Advanced Solid Tumors
02/25/19 Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis
02/20/19 Alkermes to Present at the 8th Annual SVB Leerink Global Healthcare Conference
02/19/19 Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer Therapies
02/14/19 Alkermes Plc Reports Financial Results for the Year Ended Dec. 31, 2018 and Provides Financial Expectations for 2019
02/07/19 Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results
02/01/19 Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application
01/16/19 Alkermes Announces Recipients of 1st Annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program
Displaying 76 - 90 of 795